期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗血小板治疗的研究进展 被引量：6

Advances of Antiplatelet Therapies
下载PDF
导出
摘要 抗血小板治疗可明显改善心肌缺血患者预后。现综述抗血小板治疗的进展,包括传统药物阿司匹林、噻吩并吡啶类、血小板膜糖蛋白受体拮抗剂、西洛他唑等,新型抗血小板制剂及其药代动力学、药物遗传学方面的差异、作用机制、临床相关证据、不良反应等,并简要介绍了抗血小板药物的联用。 Antiplatelet therapies have significantly improved outcomes in patients with ischemic heart disease.This paper reviews the advances of antiplatelet therapy,evolve as pharmacokinetics,pharmacogenetics,mechanism of action,clinical evidence and adverse reactions of aspirin,thienopyridines,glycoprotein Ⅱb / Ⅲa inhibitors,cilostazol and newer agents,along with combinations of antiplatelet therapies.
作者 张辉 卢新政
机构地区 南京医科大学第一附属医院心内科
出处 《心血管病学进展》 CAS 2013年第4期533-537,共5页 Advances in Cardiovascular Diseases
关键词 抗血小板药 阿司匹林 噻吩并吡啶 血小板膜糖蛋白抑制剂 替卡格雷 西洛他唑 antiplatelet agents aspirin thienopyridines GP Ⅱb /Ⅲa inhibitors ticagrelor cilostazol
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献21

  • 1Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standmd- dose elopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention fir acute coronary syndromes ( CURRENT- OASIS 7 ) : a randomised facttrial trial[ J ]. Lancet ,2010,376 : 1233-1243.
  • 2Ruppreeht H J, Widimsky P, Atzal R, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes [ J ]. N Engl J Med, 2010,363 : 930- 942.
  • 3Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytoehlome P450 enzymes involved in the two oxidative steps in the bioactivation of clopi- dogrel to its pharmacologically active metabolite [ J ]. Drug Metabol Dispos, 2010,38:92-99.
  • 4Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors an the antiplatelet effects of clopidogrel[J]. Thromb Haemost,2009,101:714-719.
  • 5Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease[ J]. N Engl J Med,2010,363:1909-1917.
  • 6Neubaner H, Engelhardt A, Kruger JC, et al. Pantoprazole does not influence the antiplatelet effect of clopiodgrel: a whole blood aggregometry study 'after eor- unary stenting[ J ]. J Cardiovasc Pharmacol, 2010,56:91-97.
  • 7Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel[ J]. N Engl J Med,2009,360:354-362.
  • 8Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to elopidogrel and cardiovascular events [ J ]. N Engl J Med, 2009,360 : 363- 375.
  • 9ACCF/ACG/AHA 2010 Expert consensus document on the concomitant use of proton pmnp inhibitors and thienopyridines: a focused update of the ACCF/ ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatclct therapy and NSAIDS use[J]. JACC,2010,56:2052-2064.
  • 10Bonello L, Tantry US, Mareucei R, et ai. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphatc [J]. JACC ,2010,56:919-933.

同被引文献55

  • 1关键,王国干,朱俊.直接凝血酶抑制剂及其临床应用[J].首都医科大学学报,2007,28(4):462-466. 被引量：1
  • 2无.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206. 被引量：2058
  • 3SPRINGTHORPE B, BEILEY A, BARTON P, et al. From ATP to AZD6140 : the discovery of an orally active reversible P2YI2 receptor antagonist for the prevention of thrombosis [ J ]. Bioorg Med Chem Lett,2007,17(21 ) :6013 - 6018.
  • 4ALI E,GRIESSMERER K J, MULLER C E, et al. Synthesis and preliminary evaluation of [3H ] PSB- 0413, a selective antagonist radioligand for platelet P2Y12 receptors [J].Bioorg Med Chem Lett,2005, 15 ( 24 ) :5450 - 5452.
  • 5DOUGLASS J G,DECAMP J B,FULCHER E H,et al. Adenosine analogues as inhibitors of P2Y12 re- ceptor mediated platelet aggregation[J]. Bioorg Med Chem Lett,2008,18 ( 6 ) : 2167 - 2171.
  • 6LIU H, GE H, PENG Y, et al. Molecular mechanism of action for reversible P2Y12 antagonists [J]. Bio- phys Chem,2011,155 ( 2 ) :74 - 81.
  • 7姚懿,袁晋青.新型抗血小板药物普拉格雷、替格瑞洛与氯吡格雷的临床对比研究进展[J].中华临床医师杂志,2013,7(19):8870-8873.
  • 8RAO T, ZHANG C Z. Cyclopropyl modulators of P2Y12 receptor :WO,2011017108 [ P ]. 2011 - 10 - 02.
  • 9RANGANATHAN S, SHAJIG K. 2-Aza-3-oxabicy- clo [ 2.2. 1 ] heptane hydrochloride : an exceptionally versatile synthon for carbocyclic sugars and nucleo- sides [ J ]. Tetrahedron, 1997,53 ( 9 ) : 3347 - 3362.
  • 10ZHANG H, LIU J, ZHANG L Y, et al. Synthesis and biological evaluation of ticagrelor derivatives as no- vel antiplatelet agents [ J ]. Bioorg Med Chem Lett, 2012,22( 11 ) :3598 - 3602.

引证文献6

二级引证文献19

心血管病学进展
2013年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部